Veraxa Biotech (NASDAQ:VRXA – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Monday.
Veraxa Biotech Trading Up ∞
Shares of VRXA traded up $1.35 during trading hours on Monday, reaching $1.35. The stock had a trading volume of 294,506 shares, compared to its average volume of 552,236. Veraxa Biotech has a 12 month low of $1.32 and a 12 month high of $27.36.
Insiders Place Their Bets
In other Veraxa Biotech news, Director Oliver Rolf Baumann acquired 50,000 shares of the stock in a transaction on Thursday, August 27th. The shares were purchased at an average price of $1.50 per share, for a total transaction of $75,000.00. Following the completion of the acquisition, the director owned 5,773,618 shares in the company, valued at approximately $8,660,427. This represents a 0.87% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
About Veraxa Biotech
Veraxa Biotech AG is a biotechnology company focused on developing targeted antibody-based medicines, with an emphasis on antibody-drug conjugates (ADCs). These therapies are designed to use antibodies to identify specific cells and deliver therapeutic agents more selectively.
The company’s work includes antibody discovery, therapeutic development and the design of ADC candidates that combine targeting antibodies with drug payloads. Its research is directed primarily toward potential treatments for cancer and other serious diseases, although specific development programs and product approvals may change as its pipeline advances.
Publicly available information about Veraxa Biotech’s corporate history, geographic operations and leadership is limited.
Featured Articles
- Five stocks we like better than Veraxa Biotech
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for Veraxa Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veraxa Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
